Allergan (NYSE:AGN) said today that it won FDA approval for its Xen gel stent and injector for glaucoma. The federal watchdog indicated the drug device for the management of refractory glaucoma, in cases where surgical treatment has failed or in patients with open angle glaucoma that is unresponsive to maximum tolerated medical therapy.
The Dublin-based company’s device is implanted ab interno, reducing intraocular pressure by forming a new drainage channel with a flexible, permanent implant.
Get the full story at our sister site, Drug Delivery Business News
The post FDA clears Allergan’s Xen gel stent for glaucoma appeared first on MassDevice.
from MassDevice http://ift.tt/2gcs2EP
Cap comentari:
Publica un comentari a l'entrada